<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><description>BiG，Biologics Innovation Group是由致力于从事生物医药领域研究、开发、应用、临床、投资等工作的独立个人，自愿组织的一个专业/非盈利性机构。正式成立于2014年，迄今会员490余人，相继举办20余场行业峰会。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sat, 06 Mar 2021 11:47:32 +0800</pubDate><image><url>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</url><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>折戟路上的勇士！如何通过临床策略提升ADC成功率？</title><link>https://mp.weixin.qq.com/s/-wibTYu2ciHsWeoP7kE3TQ</link><description></description><content:encoded><![CDATA[折戟路上的勇士！如何通过临床策略提升ADC成功率？]]></content:encoded><pubDate>Fri, 05 Mar 2021 21:35:00 +0800</pubDate></item><item><title>Moderna公布IL-12 mRNA肿瘤疫苗I期数据，联用Durvalumab效果可期</title><link>https://mp.weixin.qq.com/s/-mgaAjHM-rWwM3yhBv6ZOw</link><description></description><content:encoded><![CDATA[Moderna公布IL-12 mRNA肿瘤疫苗I期数据，联用Durvalumab效果可期]]></content:encoded><pubDate>Thu, 04 Mar 2021 18:26:43 +0800</pubDate></item><item><title>免疫单药真的落寞了么，双抗市场究竟蓝海多大？</title><link>https://mp.weixin.qq.com/s/HUjzyzoM77IcpUomM9LIZA</link><description></description><content:encoded><![CDATA[免疫单药真的落寞了么，双抗市场究竟蓝海多大？]]></content:encoded><pubDate>Wed, 03 Mar 2021 17:04:13 +0800</pubDate></item><item><title>缺氧耐药新解法！贝伐珠单抗难治性GBM 2期达到主要终点</title><link>https://mp.weixin.qq.com/s/lWm4o7yj24kobzPJksNxSQ</link><description></description><content:encoded><![CDATA[缺氧耐药新解法！贝伐珠单抗难治性GBM 2期达到主要终点]]></content:encoded><pubDate>Mon, 01 Mar 2021 17:12:48 +0800</pubDate></item><item><title>信达生物新冠抗体项目美国FDA IND获批，苏桥助力2000L GMP生产</title><link>https://mp.weixin.qq.com/s/xTCYtnj4N4VgnqPafbGZYA</link><description></description><content:encoded><![CDATA[信达生物新冠抗体项目美国FDA IND获批，苏桥助力2000L GMP生产]]></content:encoded><pubDate>Mon, 01 Mar 2021 17:12:48 +0800</pubDate></item><item><title>百花齐放！常见双特异性抗体技术平台</title><link>https://mp.weixin.qq.com/s/nPIdl0-0FASlqh_LYXoAhA</link><description></description><content:encoded><![CDATA[百花齐放！常见双特异性抗体技术平台]]></content:encoded><pubDate>Sat, 27 Feb 2021 22:22:03 +0800</pubDate></item><item><title>4-1BB+T细胞：免疫治疗革命的主角</title><link>https://mp.weixin.qq.com/s/D4pDhkRvytBPW3rH0NFBhw</link><description></description><content:encoded><![CDATA[4-1BB+T细胞：免疫治疗革命的主角]]></content:encoded><pubDate>Fri, 26 Feb 2021 17:56:16 +0800</pubDate></item><item><title>新江湖｜医普科诺加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/mFMUuGfa3Xmx5TbjLtmHMw</link><description></description><content:encoded><![CDATA[新江湖｜医普科诺加入BiG会员机构！]]></content:encoded><pubDate>Fri, 26 Feb 2021 17:56:16 +0800</pubDate></item><item><title>双特异性纳米抗体，激活1型NKT细胞</title><link>https://mp.weixin.qq.com/s/vYG2X0q93FPymhsDu0aIeQ</link><description></description><content:encoded><![CDATA[双特异性纳米抗体，激活1型NKT细胞]]></content:encoded><pubDate>Tue, 23 Feb 2021 15:17:59 +0800</pubDate></item><item><title>抗Galectin-9与GITR激动剂的协同抗肿瘤作用</title><link>https://mp.weixin.qq.com/s/9sntacAt2lvp0GOAotOmwg</link><description></description><content:encoded><![CDATA[抗Galectin-9与GITR激动剂的协同抗肿瘤作用]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:03:52 +0800</pubDate></item><item><title>以IL-2/IL-2R经典传奇，开启新的十年！</title><link>https://mp.weixin.qq.com/s/MqPAUzIITKSY-5sHh2lJBQ</link><description></description><content:encoded><![CDATA[以IL-2/IL-2R经典传奇，开启新的十年！]]></content:encoded><pubDate>Thu, 18 Feb 2021 16:55:42 +0800</pubDate></item><item><title>低毒有效！“睡美人” CAR-T I/II期临床试验结果</title><link>https://mp.weixin.qq.com/s/otcr9WCq5mRU0O7I-U8kUQ</link><description></description><content:encoded><![CDATA[低毒有效！“睡美人” CAR-T I/II期临床试验结果]]></content:encoded><pubDate>Thu, 18 Feb 2021 16:50:27 +0800</pubDate></item></channel></rss>